To date, immunotherapy is considered to be the most promising systemic oncology treatment compared to traditional anti-cancer treatment strategies, among which monoclonal antibodies have become a key modality for cancer treatment due to their targeted therapeutic effects. However, due to the complex disease pathogenesis of tumors, monoclonal antibodies against a single target are often insufficient to exhibit sufficient therapeutic effects. Therefore, bispecific antibodies (BsAbs) against multiple targets have emerged, and their development has changed the field of tumor immunotherapy. It is well known that PD-1/PDL1, as a star immune checkpoint, molecular blockade, has a wide application in the immunotherapy of tumors. However, PD-1/PDL1 blockade had limited therapeutic efficacy, (&lt;30% response rate) and often ocurred adaptive resistance.TIGIT is a novel immune checkpoint molecule expressed on NK and T cells, whose ligand is on APC (antigen-presenting cells and tumor cells) PVR. Here, we designed a novel PDL1-TIGIT dual antibody to co-assemble peptide-based material that can dual target PDL1 on tumor cells and TIGIT on NK/T cells, blocking the immune checkpoint and relieving immunosuppression and restoring T/NK immune activity. Meanwhile, the co-assembled peptide can pull the peptide and immune cells close to each other, thus recruiting more immune cells around tumor tissues and enhancing tumor therapeutic ability. Compared with protein antibodies, self-assembled peptides have the advantages of simple synthesis, low cost, resistance to hydrolysis, and better tumor infiltration and tissue retention.

Novel bispecific nanomaterials with PD-L1/TIGIT dual immune checkpoint blockade by peptide-co-assembled

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.